Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive diseases in China: a

Jinjian Fu1,2, Rongsong Yi3, Yongjiang Jiang4

  • 1Department of Laboratory Medicine, Liuzhou Maternity and Child Health Care Hospital, Liuzhou, 545001, Guangxi, China.

BMC Pediatrics
|November 13, 2019
PubMed

Insights

Invasive pneumococcal disease (IPD) in China is primarily caused by serotypes 19F, 19A, and 14. The pneumococcal conjugate vaccine PCV13 covers 90% of these serotypes, offering significant health benefits for children.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Microbiology

Background:

  • Invasive pneumococcal disease (IPD) poses a significant threat to children's health globally.
  • Understanding the epidemiology of IPD, including prevalent serotypes and antibiotic resistance patterns, is crucial for effective prevention and control strategies.

Purpose of the Study:

  • To systematically review and summarize the available data on IPD in children in mainland China.
  • To identify the predominant Streptococcus pneumoniae serotypes and assess their antibiotic resistance profiles.
  • To evaluate the potential impact of pneumococcal conjugate vaccines (PCVs) in the Chinese context.

Main Methods:

  • A systematic review of 16 eligible studies was conducted.
  • A random-effects model was employed to estimate the pooled prevalence of IPD.
  • Serotype distribution, vaccine coverage, and antibiotic resistance rates were analyzed.

Main Results:

  • The most prevalent serotypes were 19F (27.7%), 19A (21.2%), and 14 (16.5%).
  • Pneumococcal conjugate vaccine PCV13 demonstrated 90% serotype coverage.
  • High rates of antibiotic resistance were observed, with 32.0% resistance to penicillin and over 90% resistance to erythromycin and clindamycin.

Conclusions:

  • PCV13 exhibits high coverage for the predominant serotypes causing IPD in Chinese children.
  • The high prevalence of antibiotic-resistant strains underscores the importance of vaccination.
  • Implementing PCV13 into China's Expanded Program on Immunizations (EPI) is recommended to improve public health outcomes.
Abstract